Jubilant Life Sciences receives ANDA approvals for Valsartan Tablets
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated January 06, 2015 titled "Jubilant Life Sciences receives ANDA approvals for Valsartan Tablets". Appointment of Mr. GP Singh as CEO - Jubilant Pharma
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated January 06, 2015, titled "Appointment of Mr. GP Singh as CEO - Jubilant Pharma". Jubilant Life Sciences receives ANDA approvals for Mycophenolate Mofetil and Rizatriptan
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated January 05, 2015, titled "Jubilant Life Sciences receives ANDA approvals for Mycophenolate Mofetil and Rizatriptan". Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc.
Jubilant Life Sciences Ltd has submitted to BSE regarding a Press Release dated December 23, 2014 titled "Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc." Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Tender Offer by Jubilant Pharma Ltd, a subsidiary of Jubilant Life Sciences Ltd
Jubilant Life Sciences Ltd has informed BSE that Jubilant Pharma Limited ("JPL"), a Singapore company and wholly-owned subsidiary of Jubilant Life Sciences Limited, through Jubilant Generics Inc., a Delaware corporation and an indirect wholly-owned subsidiary of JPL, ("Jubilant Generics") has commenced a Tender Offer to acquire all outstanding shares of common stock (collectively, the "Shares") of Cadista Holdings Inc., a Delaware corporation ("Cadista"),... Announces Q2 results, Results Press Release & Limited Review Report for the Quarter ended September 30, 2014
Jubilant Life Sciences Ltd has announced the following results for the quarter ended September 30, 2014:"The Unaudited Standalone results for the Quarter ended September 30, 2014The Company has posted a net profit of Rs. 2167.60 million for the quarter ended September 30, 2014 where as the same was at net loss of Rs. (785.80) million for the quarter ended September 30, 2013. Total Income is Rs. 7530.30 million for the quarter ended... Q2 results on Oct 28, 2014
Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 28, 2014, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014 (Q2).Further, as per the Company's Insider Trading Code, the Trading Window for dealing in the securities of the Company would remain closed for all Directors/Officers/Designated Employees...